The malaria testing and treatment landscape in Kenya: results from a nationally representative survey among the public and private sector in 2016

Malaria Journal

Research

Waqo Ejersa¹  Rebecca Kiptui¹  Dorothy Memusi¹  Edward Abwao²  Anne Musuva³ 

[1] National Malaria Control Programme, Kenya KNH Grounds, P.O. Box 20750, Nairobi, Kenya;Pharmacy and Poisons Board, Nairobi, Kenya;Population Services Kenya (PS/Kenya), P.O. Box 22591-00400, 2nd Floor, Wing B, Jumuia Place, Lenana Road, Nairobi, Kenya;

关键词: Malaria control case management;    Anti-malarial;    ACT;    Private sector;    Public sector;    Malaria diagnosis;    Kenya;   

DOI  :  10.1186/s12936-017-2089-0

 received in 2017-06-08, accepted in 2017-10-27,  发布年份 2017

来源: Springer

【 摘 要 】

BackgroundSince 2004, Kenya’s national malaria treatment guidelines have stipulated artemisinin-based combination therapy (ACT) as first-line treatment for uncomplicated malaria, and since 2014, confirmatory diagnosis of malaria in all cases before treatment has been recommended. A number of strategies to support national guidelines have been implemented in the public and private sectors in recent years. A nationally-representative malaria outlet survey, implemented across four epidemiological zones, was conducted between June and August 2016 to provide practical evidence to inform strategies and policies in Kenya towards achieving national malaria control goals.ResultsA total of 17,852 outlets were screened and 2271 outlets were eligible and interviewed. 78.3% of all screened public health facilities stocked both malaria diagnostic testing and quality-assured ACT (QAACT). Sulfadoxine–pyrimethamine (SP) for intermittent preventive treatment in pregnancy was available in 70% of public health facilities in endemic areas where it is recommended for treatment. SP was rarely found in the public sector outside of the endemic areas (< 0.5%). The anti-malaria stocking private sector had lower levels of QAACT (46.7%) and malaria blood testing (20.8%) availability but accounted for majority of anti-malarial distribution (70.6% of the national market share). More than 40% of anti-malarials were distributed by unregistered pharmacies (37.3%) and general retailers (7.1%). QAACT accounted for 58.2% of the total anti-malarial market share, while market share for non-QAACT was 15.8% and for SP, 24.8%. In endemic areas, 74.9% of anti-malarials distributed were QAACT. Elsewhere, QAACT market share was 49.4% in the endemic-prone areas, 33.2% in seasonal-transmission areas and 37.9% in low-risk areas.ConclusionAlthough public sector availability of QAACT and malaria diagnosis is relatively high, there is a gap in availability of both testing and treatment that must be addressed. The private sector in Kenya, where the majority of anti-malarials are distributed, is also critical for achieving universal coverage with appropriate malaria case management. There is need for a renewed commitment and effective strategies to ensure access to affordable QAACT and confirmatory testing in the private sector, and should consider how to address malaria case management among informal providers responsible for a substantial proportion of the anti-malarial market share.

【 授权许可】

CC BY   
© The Author(s) 2017